BRIEF-Prokidney Corp to sell Greensboro property for $19.1 million - SEC filing

Reuters10-18
BRIEF-Prokidney Corp to sell Greensboro property for $19.1 million - SEC filing

Oct 17 (Reuters) - Prokidney Corp PROK.O:

  • PROKIDNEY CORP - TO SELL GREENSBORO PROPERTY FOR $19.1 MILLION - SEC FILING

Source text: [ID:n0001193125-25-242565]

Further company coverage: PROK.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Cedric77
    10-29
    Cedric77
    If you’re considering buying ProKidney Corp. (ticker PROK) for the long term, one compelling reason is: > Potential of its lead therapy to address a large unmet medical need. ProKidney is developing a cell-therapy platform (namely REACT / “renal autologous cell therapy”) aimed at treating chronic kidney disease (CKD) in diabetic patients, a market with few disease-modifying options. Because CKD affects many people and presents serious complications (e.g., kidney failure, dialysis), if REACT succeeds in later-stage trials and gets regulatory approval, the company could have a strong growth opportunity. Cautious: The company is still in clinical stage (no commercial product yet), so there is significant risk of trial failure or regulatory setbacks. Analysts are mixed: some bullish (high u
Leave a comment
1
1